|
Delayed
OTC Markets
20:10:00 2024-01-24 EST
|
5-day change | 1st Jan Change | ||
| 13.33 USD | -.--% |
|
-.--% | - |
| 25-03-30 | Ultimovacs ASA(OB:ULTI) dropped from Next Biotech Index | CI |
| 25-03-04 | Ultimovacs ASA will Change its Name to Zelluna ASA | CI |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
EBT: Breakdown by Business Segment
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Biological Products | ||||||||||
Net Income | -121M | -165M | -168M | -189M | -201M | |||||
D&A | 2.72M | 2.7M | 2.65M | 2.77M | 2.77M | |||||
Operating Income | -124M | -164M | -184M | -216M | -224M | |||||
EBT | -121M | -165M | -168M | -189M | -213M | |||||
CAPEX | -5.28M | -85K | -195K | -25K | -17K | |||||
Income Tax Expense | - | - | - | - | -11.65M | |||||
Interest Expense | -240K | -333K | -243K | -382K | -299K | |||||
Total Assets | 530M | 656M | 510M | 349M | 116M |
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Operating Income | -124M | -164M | -184M | -216M | -224M | |||||
Net Income | -121M | -165M | -168M | -189M | -201M | |||||
EBT | -121M | -165M | -168M | -189M | -213M | |||||
CAPEX | -5.28M | -85K | -195K | -25K | -17K | |||||
D&A | 2.72M | 2.7M | 2.65M | 2.77M | 2.77M | |||||
Income Tax Expense | - | - | - | - | -11.65M | |||||
Interest Expense | -240K | -333K | -243K | -382K | -299K | |||||
Total Assets | 530M | 656M | 510M | 349M | 116M |
- Stock Market
- Stocks
- ULTI Stock
- ULTMF Stock
- Financials Ultimovacs ASA
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
